Dermapharm
Corporate brand
UnclaimedDermapharm is a German pharmaceutical group focused on dermatological, allergological and other primarily generic medicines, with manufacturing concentrated in Germany.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Dermapharm is the corporate brand of Dermapharm Holding SE, a German pharmaceutical group headquartered in Grünwald near Munich. Founded in 1991 by Wilhelm Beier, the company developed around the manufacture and distribution of medicines, with particular expertise in dermatological and allergological preparations. Its portfolio is primarily composed of generic medicines, supplemented by products in areas such as consumer health, sun protection, medical cannabis and allergy treatment. The company has maintained a strong German manufacturing base. Its subsidiary mibe GmbH Arzneimittel operates a production site in Brehna near Leipzig, while the wider group has historically manufactured almost all of its products in Germany. Dermapharm’s commercial footprint extends beyond Germany through sites and activities in Austria, Switzerland, Croatia, Poland, Ukraine, the United Kingdom, Italy and Spain. This combination of domestic production and international distribution forms a central part of the group’s operating model. Dermapharm’s corporate development has included both organic expansion and acquisitions. A proposed sale to investors did not proceed in 2016. In 2018, the Beier family sold 19.3% of its shares in connection with the company’s initial public offering, while retaining approximately 65% of the outstanding shares according to the referenced company history. The group subsequently broadened its portfolio through acquisitions, including Allergopharma from Merck KGaA, announced in February 2020. Allergopharma specializes in allergy treatments and added a distinct allergology platform to Dermapharm’s existing pharmaceutical activities. The COVID-19 pandemic brought Dermapharm into contract manufacturing for BioNTech’s COVID-19 vaccine tozinameran. Production began at the Brehna facility after October 2020, followed from the end of April 2021 by production at Allergopharma’s site in Reinbek. This activity was conducted on behalf of BioNTech and represented a significant expansion of the group’s manufacturing role beyond its established dermatology and generic-drug focus. In early 2022, Dermapharm acquired the C³ Group, subsequently associated with Candoro ethics today, from Canopy Growth Corporation. The business was connected with medical cannabis and had previously been part of Bionorica. Other companies identified within the Dermapharm Group include acis Arzneimittel, which focuses on generics; Anton Hübner, associated with health-food products; Tiroler Nussöl Sonnenkosmetik, focused on sun protection; Axicorp, active in generics and reimports; and Trommsdorff and Strathmann. Dermapharm’s positioning therefore combines pharmaceutical manufacturing, branded and generic medicines, specialist therapeutic areas and selected consumer-health businesses. Its identity is less that of a single over-the-counter product brand than that of a diversified healthcare group operating through a portfolio of subsidiaries and product families. The available reference material does not provide a complete current product catalogue, detailed financial results, a current executive roster or a current stock ticker, so those fields remain limited where information cannot be verified.
History
Dermapharm was founded in 1991 by Wilhelm Beier as a German pharmaceutical company focused on the manufacture and distribution of medicines. Its specialist identity developed around dermatological and allergological preparations, while generic medicines became the principal component of its broader portfolio. The company has been based in Grünwald near Munich since 1998, giving the group a corporate base in the Munich metropolitan area while retaining manufacturing activities elsewhere in Germany. A defining feature of Dermapharm’s model is the use of German production facilities. Through mibe GmbH Arzneimittel, the group operates a site in Brehna near Leipzig. The referenced company description states that almost all of Dermapharm’s products are manufactured in Germany. At the same time, the group established or maintained operations in several European markets, including Austria, Switzerland, Croatia, Poland, Ukraine, the United Kingdom, Italy and Spain. The result is a structure combining domestic manufacturing with cross-border commercial and group operations. Dermapharm’s ownership and capital structure changed during the 2010s. An attempted sale to investors failed in 2016. Two years later, the Beier family sold 19.3% of its shares as part of Dermapharm’s initial public offering. The family was reported to retain approximately 65% of the outstanding shares after the offering, preserving family influence while making the company publicly listed. The group expanded beyond its original specialist focus through a portfolio of subsidiaries. Acis Arzneimittel added generic-drug activities; Anton Hübner contributed health-food products; Tiroler Nussöl Sonnenkosmetik represented sun-protection products; Axicorp covered generics and reimports; and Trommsdorff and Strathmann formed additional pharmaceutical businesses within the group. In February 2020, Merck KGaA announced the sale of Allergopharma to Dermapharm. Allergopharma’s specialization in allergy treatment strengthened Dermapharm’s presence in allergology and added the Reinbek site to its manufacturing network. The COVID-19 pandemic created a new manufacturing role for the company. After October 2020, Dermapharm produced BioNTech’s tozinameran vaccine at the Brehna facility. From the end of April 2021, production also started at Allergopharma’s Reinbek site. This was contract production on behalf of BioNTech rather than a change in Dermapharm’s core identity, but it demonstrated the capacity of its German manufacturing infrastructure to support a high-profile vaccine supply chain. In early 2022, Dermapharm acquired the C³ Group from Canopy Growth Corporation. The business was connected with medical cannabis and was formerly part of Bionorica; it later used the Candoro ethics today name. This transaction added medical cannabis to the group’s set of healthcare activities. Across these developments, Dermapharm evolved from a specialist German pharmaceutical manufacturer into a diversified, publicly listed healthcare group with generic medicines at its center, specialist dermatology and allergology capabilities, consumer-health activities, international operations and selected contract-manufacturing and medical-cannabis interests.
- 2022
C³ Group acquired
[1]Dermapharm acquired the C³ Group, connected with medical cannabis, from Canopy Growth Corporation.
- 2021
Reinbek vaccine production added
[1]Production of tozinameran began at the Allergopharma site in Reinbek at the end of April 2021.
- 2020
Allergopharma acquisition announced
[1]Merck KGaA announced the sale of Allergopharma, an allergy-treatment specialist, to Dermapharm.
- 2020
Tozinameran production begins
[1]Dermapharm began producing BioNTech’s COVID-19 vaccine at the Brehna facility after October 2020.
- 2018
Initial public offering
[1]The Beier family sold 19.3% of its shares during the IPO and retained approximately 65% of the outstanding shares according to the referenced history.
- 2016
Proposed investor sale fails
[1]An attempted sale of Dermapharm to investors did not proceed.
- 1998
Headquarters established in Grünwald
[1]The company has been based in Grünwald near Munich since 1998.
- 1991
Dermapharm founded
[1]Wilhelm Beier founded Dermapharm as a German pharmaceutical company focused on medicines and specialist preparations.
Products and positioning
A German pharmaceutical group combining generic-drug development and distribution with specialist dermatology and allergology, German manufacturing, international operations and selected consumer-health and medical-cannabis businesses.
Pharmaceuticals
Generic medicines
Generic medicines form the main body of Dermapharm’s portfolio. They are manufactured and distributed through the group and associated companies such as acis Arzneimittel and Axicorp. The available reference material does not identify individual active ingredients or therapeutic brands, so this entry describes the category rather than assigning specific products.
Dermatology
Dermatological preparations
Dermatological preparations are one of Dermapharm’s defining specialist areas. The group is described as specializing in the manufacture and distribution of dermatological medicines, alongside its wider generic-drug portfolio. The supplied sources do not provide a sufficiently detailed list of individual formulations.
Allergology
Allergological preparations
Allergological products are another core specialist area. The acquisition of Allergopharma from Merck KGaA strengthened this segment by adding a company focused on allergy treatments and a production site in Reinbek.
Vaccine manufacturing · 2020
Tozinameran contract manufacturing
Dermapharm manufactured BioNTech’s tozinameran COVID-19 vaccine on a contract basis. Production was reported at the mibe facility in Brehna after October 2020 and at the Allergopharma site in Reinbek from the end of April 2021. This was a manufacturing service for BioNTech rather than a Dermapharm-owned vaccine brand.
Consumer health
Sun-protection products
The group’s portfolio includes sun-protection products through Tiroler Nussöl Sonnenkosmetik. The source material identifies the business area but does not specify individual product names or formulations.
Medical cannabis · 2022
Medical-cannabis products
Dermapharm entered or expanded its medical-cannabis activities through the 2022 acquisition of the C³ Group from Canopy Growth Corporation. The business had previously been part of Bionorica and was associated with the Candoro ethics today name.
Brand decisions
2022
Acquisition of C³ GroupM&ABackground
The C³ Group operated in medical cannabis and had previously been part of Bionorica before being acquired by Canopy Growth Corporation.
Action taken
Dermapharm acquired the C³ Group from Canopy Growth Corporation in early 2022.
Aftermath
The transaction broadened Dermapharm’s healthcare portfolio to include a medical-cannabis business associated with Candoro ethics today.
2020
Acquisition of AllergopharmaM&ABackground
Allergopharma specialized in allergy treatments and was offered for sale by Merck KGaA.
Action taken
Merck KGaA announced the sale of Allergopharma to Dermapharm in February 2020.
Aftermath
The acquisition expanded Dermapharm’s allergology portfolio and added the Reinbek production site to its operations.
2020
COVID-19 vaccine manufacturing agreementProduct launchBackground
BioNTech required additional manufacturing capacity for its COVID-19 vaccine, tozinameran.
Action taken
Dermapharm produced the vaccine at its Brehna facility on behalf of BioNTech after October 2020.
Aftermath
Dermapharm’s German manufacturing network contributed to the vaccine supply chain, with additional production later added at Reinbek.
2018
Public offering with continued family controlStrategyBackground
Dermapharm pursued a public listing after an earlier investor sale had failed in 2016. The Beier family remained the controlling shareholder after the offering.
Action taken
The family sold 19.3% of its shares in the IPO while retaining approximately 65% of the outstanding shares, according to the referenced company history.
Aftermath
Dermapharm became a publicly listed pharmaceutical group while retaining substantial family ownership.
Recent events
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/dermapharm · Editorial policy · How profiles are compiled